Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHD-609 in Advanced Synovial Sarcoma or SMARCB1-Loss Tumors
NCT04965753Phase 1Terminated
- Sponsor
- Foghorn Therapeutics
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of FHD-609 in synovial sarcoma (SS) and SMARCB1-deficient tumors, sponsored by Foghorn Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 31 months, Incidence of Adverse Events and Serious Adverse Events up to 31 months and 1 more. Started Aug 2021; status: terminated.
02
Drugs
FHD-609
03
Conditions
synovial sarcoma (SS)SMARCB1-deficient tumors
Beyond the preview
Go deeper on NCT04965753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965753.